Published in AIDS Res Hum Retroviruses on February 01, 2009
Research In Viral Eradication of HIV Reservoirs (RIVER) | NCT02336074
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med (2014) 2.76
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
HIV: Shock and kill. Nature (2012) 2.45
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature (2015) 2.41
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem (2010) 2.23
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog (2013) 2.16
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09
Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog (2013) 2.02
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS (2011) 2.00
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2014) 1.96
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
Prospects for treatment of latent HIV. Clin Pharmacol Ther (2012) 1.91
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell (2014) 1.91
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog (2014) 1.88
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88
Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep (2012) 1.84
Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol (2011) 1.82
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest (2015) 1.76
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res (2012) 1.73
Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol (2015) 1.73
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis (2012) 1.72
An integrated overview of HIV-1 latency. Cell (2013) 1.68
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog (2011) 1.64
Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol (2011) 1.61
Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog (2014) 1.59
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother (2013) 1.53
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis (2010) 1.45
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem (2011) 1.45
Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med (2011) 1.41
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
Developing strategies for HIV-1 eradication. Trends Immunol (2012) 1.38
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology (2011) 1.31
Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med (2011) 1.30
Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods (2010) 1.29
Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res (2011) 1.23
The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr (2010) 1.22
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A (2012) 1.19
Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc (2011) 1.18
Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem (2013) 1.17
HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS (2013) 1.15
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. MBio (2015) 1.13
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12
T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J Mol Biol (2011) 1.12
Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse. J Virol (2011) 1.11
HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND). Neurochem Int (2011) 1.09
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog (2013) 1.08
From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays (2013) 1.07
Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomedicine (2015) 1.07
A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J Virol (2013) 1.07
Framing expectations in early HIV cure research. Trends Microbiol (2014) 1.06
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS (2014) 1.05
An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol (2012) 1.04
Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder. Mol Brain (2014) 1.02
Eradication therapies for HIV Infection: time to begin again. AIDS Res Hum Retroviruses (2011) 0.99
Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother (2014) 0.99
Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis (2013) 0.99
Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology (2014) 0.99
Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Mol Ther (2015) 0.98
Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics (2015) 0.98
Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J (2010) 0.98
High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem (2011) 0.97
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? Mol Ther (2013) 0.95
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol (2012) 0.95
Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS (2013) 0.94
Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res Hum Retroviruses (2015) 0.94
Finding a cure for human immunodeficiency virus-1 infection. Infect Dis Clin North Am (2014) 0.93
HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology (2013) 0.93
Histone deacetylases in viral infections. Clin Epigenetics (2010) 0.93
Latency reversal and viral clearance to cure HIV-1. Science (2016) 0.92
Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One (2014) 0.92
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother (2014) 0.92
Opportunities to exploit non-neutralizing HIV-specific antibody activity. Curr HIV Res (2013) 0.91
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathog (2016) 0.90
Broad activation of latent HIV-1 in vivo. Nat Commun (2016) 0.90
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Epigenetic regulation of HIV-1 latency in astrocytes. J Virol (2013) 0.89
Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. J Biol Chem (2014) 0.89
A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region. Retrovirology (2014) 0.89
Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One (2013) 0.88
Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. J Virol (2016) 0.88
HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad (2015) 0.87
Translating the histone code. Science (2001) 56.77
The language of covalent histone modifications. Nature (2000) 44.92
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Histone acetylation and an epigenetic code. Bioessays (2000) 8.84
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 6.16
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J (1996) 5.10
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 4.95
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J (2001) 3.80
Discovery and development of SAHA as an anticancer agent. Oncogene (2007) 3.58
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol (2002) 2.64
Dilution assay statistics. J Clin Microbiol (1994) 2.61
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52
Histone acetylation reduces nucleosome core particle linking number change. Cell (1989) 2.41
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev (1996) 2.07
Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol (1994) 1.98
Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol (1998) 1.90
Histone acetylation and chromatin remodeling. Exp Cell Res (2001) 1.85
Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev (1998) 1.69
Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis (2004) 1.64
Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell Mol Life Sci (1998) 1.58
Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol (1997) 1.48
Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev (2005) 1.46
Interaction of histone acetylases and deacetylases in vivo. Mol Cell Biol (2003) 1.35
Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol (2006) 1.29
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
Malaria in the Greater Mekong Subregion: heterogeneity and complexity. Acta Trop (2011) 2.70
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09
Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis (2007) 2.05
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97
Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc (2008) 1.84
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother (2009) 1.80
In vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genes. PLoS One (2012) 1.74
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis (2008) 1.66
Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis (2004) 1.64
Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol (2011) 1.61
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57
Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis (2014) 1.56
Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem (2003) 1.54
LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.50
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. HIV Clin Trials (2003) 1.41
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.39
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest (2011) 1.37
Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis (2008) 1.32
Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J Virol (2007) 1.30
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis (2009) 1.28
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother (2008) 1.26
Self-assembly of flexible supramolecular metallacyclic ensembles: structures and adsorption properties of their nanoporous crystalline frameworks. J Am Chem Soc (2004) 1.25
Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol (2002) 1.24
Challenges and prospects for malaria elimination in the Greater Mekong Subregion. Acta Trop (2011) 1.21
Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy (2004) 1.19
New insights into the plantar pressure correlates of walking speed using pedobarographic statistical parametric mapping (pSPM). J Biomech (2008) 1.18
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther (2008) 1.16
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA (2006) 1.14
Acute HIV-1 infection in the Southeastern United States: a cohort study. AIDS Res Hum Retroviruses (2012) 1.14
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest (2015) 1.13
The regulation of HIV-1 gene expression: the emerging role of chromatin. DNA Cell Biol (2002) 1.13
Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med (2009) 1.13
Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle (2010) 1.12
Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse. J Virol (2011) 1.11
Plasmodium falciparum populations from northeastern Myanmar display high levels of genetic diversity at multiple antigenic loci. Acta Trop (2012) 1.10
Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation. Retrovirology (2013) 1.06
Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr (2004) 1.05
Words matter: Discussing research towards an HIV cure in research and clinical contexts. J Acquir Immune Defic Syndr (2014) 1.04
Fatal ergotism induced by an HIV protease inhibitor. Headache (2002) 1.04
Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors. Sci Transl Med (2014) 1.03
Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother (2012) 1.01
Extensive lysine acetylation occurs in evolutionarily conserved metabolic pathways and parasite-specific functions during Plasmodium falciparum intraerythrocytic development. Mol Microbiol (2013) 1.00
High-throughput screening by RNA interference: control of two distinct types of variance. Cell Cycle (2007) 1.00
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS (2011) 0.99
Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother (2010) 0.98
Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr (2013) 0.95
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties. Bioorg Med Chem Lett (2005) 0.95
HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol (2014) 0.94
Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob Agents Chemother (2008) 0.94
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother (2014) 0.92
CtBP2 Promotes Human Cancer Cell Migration by Transcriptional Activation of Tiam1. Genes Cancer (2012) 0.92
Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med (2008) 0.91
Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J Med Chem (2007) 0.91
Macrocyclic inhibitors of beta-secretase: functional activity in an animal model. J Med Chem (2006) 0.90
siRNA screening of a targeted library of DNA repair factors in HIV infection reveals a role for base excision repair in HIV integration. PLoS One (2011) 0.90
Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther (2012) 0.90
Puf mediates translation repression of transmission-blocking vaccine candidates in malaria parasites. PLoS Pathog (2013) 0.90
Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res (2002) 0.89
A genome wide analysis of ubiquitin ligases in APP processing identifies a novel regulator of BACE1 mRNA levels. Mol Cell Neurosci (2006) 0.88
Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. J Med Chem (2007) 0.88
Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients. Support Care Cancer (2011) 0.87
BACE-1 inhibition by a series of psi[CH2NH] reduced amide isosteres. Bioorg Med Chem Lett (2006) 0.86
The base excision repair pathway is required for efficient lentivirus integration. PLoS One (2011) 0.86
Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane. Bioorg Med Chem Lett (2005) 0.86
Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother (2008) 0.85
Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. J Med Chem (2008) 0.85
Rational design and synthesis of selective BACE-1 inhibitors. Bioorg Med Chem Lett (2004) 0.85